These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35250578)

  • 1. Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.
    Hu S; Wang S; Qi C; Gu S; Shi C; Mao L; Fan G
    Front Pharmacol; 2022; 13():831364. PubMed ID: 35250578
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China.
    Hu S; Gu S; Qi C; Wang S; Qian F; Shi C; Fan G
    Diabetes Obes Metab; 2023 Feb; 25(2):387-397. PubMed ID: 36193880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
    Feng Z; Tong WK; Zhang X; Tang Z
    Front Pharmacol; 2023; 14():1226778. PubMed ID: 37621313
    [No Abstract]   [Full Text] [Related]  

  • 4. Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China.
    Hu S; Su X; Deng X; Wang Y
    Front Pharmacol; 2021; 12():701446. PubMed ID: 34177604
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
    Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
    Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.
    Johansen P; Håkan-Bloch J; Liu AR; Bech PG; Persson S; Leiter LA
    Pharmacoecon Open; 2019 Dec; 3(4):537-550. PubMed ID: 30927241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
    Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Kristensen MM; Ejskjaer N
    Diabetes Ther; 2022 Mar; 13(3):489-503. PubMed ID: 35187628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.
    Ruan Z; Ung COL; Shen Y; Zhang Y; Wang W; Luo J; Zou H; Xue Y; Wang Y; Hu H; Guo L
    Diabetes Ther; 2022 Oct; 13(10):1737-1753. PubMed ID: 35934763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
    Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
    Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
    Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
    BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.
    Hu S; Shi C; Ma Y; Wang S; Gu S; Qi C; Fan G
    Diabetes Obes Metab; 2024 Aug; 26(8):3176-3190. PubMed ID: 38738340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
    Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
    Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.
    Liebisch-Rey H; Suarez-Chacon AM; Fuentes YV; Blanco J; Kock J; Lechtig-Wassermann S; Bustos RH
    F1000Res; 2023; 12():914. PubMed ID: 38125558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
    Ericsson Å; Fridhammar A
    J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China.
    Liu L; Ruan Z; Ung COL; Zhang Y; Shen Y; Han S; Jia R; Qiao J; Hu H; Guo L
    Diabetes Ther; 2023 Jan; 14(1):93-107. PubMed ID: 36414806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
    Viljoen A; Chubb B; Malkin SJP; Berry S; Hunt B; Bain SC
    Eur J Health Econ; 2023 Aug; 24(6):895-907. PubMed ID: 36114904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China.
    Han G; Hu S; Zhang X; Qiu Z; Huang Z
    Front Pharmacol; 2022; 13():1011624. PubMed ID: 36467033
    [No Abstract]   [Full Text] [Related]  

  • 20. The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China.
    Gu S; Gu J; Wang X; Wang X; Li L; Gu H; Xu B
    Health Econ Rev; 2024 Apr; 14(1):26. PubMed ID: 38564113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.